Pages that link to "Q33782556"
Jump to navigation
Jump to search
The following pages link to Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity (Q33782556):
Displaying 50 items.
- Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 (Q24645530) (← links)
- Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design (Q24679395) (← links)
- Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 (Q26782237) (← links)
- Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa (Q27322437) (← links)
- The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts (Q27469663) (← links)
- Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites (Q27477542) (← links)
- The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection (Q27488224) (← links)
- Antibodies against viruses: passive and active immunization (Q27489392) (← links)
- Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates (Q27629806) (← links)
- A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies (Q27655865) (← links)
- A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield (Q27675032) (← links)
- Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign (Q27681806) (← links)
- Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes (Q27756974) (← links)
- Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. (Q28217208) (← links)
- A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies (Q28299280) (← links)
- Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry (Q28475912) (← links)
- Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 (Q30431941) (← links)
- Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. (Q30490942) (← links)
- Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 (Q30701127) (← links)
- Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. (Q31016954) (← links)
- Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library (Q31039719) (← links)
- A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. (Q31143293) (← links)
- An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 (Q33272711) (← links)
- Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity (Q33369086) (← links)
- Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 (Q33374701) (← links)
- Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. (Q33648180) (← links)
- Picornaviruses: epitopes, canyons, and pockets. (Q33671149) (← links)
- Strategies used by human immunodeficiency virus that allow persistent viral replication (Q33680601) (← links)
- Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. (Q33737656) (← links)
- Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 (Q33781344) (← links)
- Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. (Q33786382) (← links)
- Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains (Q33788810) (← links)
- Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. (Q33794954) (← links)
- Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution (Q33804811) (← links)
- Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins (Q33806056) (← links)
- Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate (Q33811940) (← links)
- Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. (Q33835295) (← links)
- Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys (Q33839485) (← links)
- Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development (Q33842152) (← links)
- Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants (Q33850415) (← links)
- Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition (Q33850612) (← links)
- Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro (Q33853775) (← links)
- Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. (Q33860721) (← links)
- Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. (Q33870236) (← links)
- Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production. (Q33921367) (← links)
- Antibodies in human infectious disease. (Q33942081) (← links)
- Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia (Q33981547) (← links)
- Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains (Q33984358) (← links)
- Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. (Q34045535) (← links)
- Assessment of HIV vaccine development: past, present, and future (Q34050712) (← links)